Neovasc Inc. Appoints GendeLLindheim BioCom Partners as Agency of Record

July 18, 2008 8:46 PM EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 18, 2008) - Neovasc Inc. (TSX VENTURE: NVC), formerly Medical Ventures Corp., a company developing and marketing specialty vascular devices, today announced it has hired GendeLLindheim BioCom Partners, LLC, as its agency of record. The firm, known as BioCom Partners, is a New York City-based public and investor relations firm that specializes in supporting the growth of emerging and established life sciences companies. BioCom Partners will provide counsel to Neovasc on investor relations efforts in the U.S. on an ongoing basis. Principals Stephen Gendel and Barbara Lindheim bring professional expertise in media, financial and investor relations to their clients. BioCom Partners has no beneficial equity interest in Neovasc and will be paid in cash on a monthly basis for the service provided. Management anticipates the fees for investor relations services will not exceed $100,000 per year.

About GendeLLindheim BioCom Partners, LLC

Founded in 2003, GendeLLindheim BioCom Partners is a full-service life sciences communications boutique. Stephen Gendel brings clients his knowledge and contacts from 25 years as an award-winning television reporter, including founding the health and science beat at business cable powerhouse CNBC. Barbara Lindheim, who holds an MBA from Harvard University, brings more than 20 years of experience as a biopharmaceutical marketing and communications executive, along with the financial savvy and contacts she acquired as an investor relations professional over the last decade. BioCom Partners is headquartered on Wall Street in New York City.

About Neovasc Inc.

Neovasc Inc. (formerly Medical Ventures Corp.) develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's current products help doctors diagnose and treat a wide range of health conditions, including vascular diseases and obesity. They include the Metricath(R) arterial and in-stent measurement system, and PeriPatch(TM) surgical tissue and staple line reinforcement products. Neovasc also provides contract medical device development and manufacturing services. For more information, visit: www.neovasc.com.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates", "believes", "may", "continues", "estimates", "expects", and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

FOR FURTHER INFORMATION PLEASE CONTACT:
        Neovasc Inc.
        Caren Holtby
        Investor Relations Manager
        (604) 270-4344 ext 110
        Fax: (604) 270-4384 (FAX)
        Email: choltby@neovasc.com

        GendeLLindheim BioCom Partners - Media Contact
        Stephen Gendel
        (212) 918-4650

        GendeLLindheim BioCom Partners - U.S. Investor Contact
        Barbara Lindheim
        (212) 918-4650

        Neovasc Inc. - Corporate Contact
        Jessica Ruffen
        Communications Manager
        (604) 248-4136
        Email: jruffen@neovasc.com
        Website: www.neovasc.com

Source: Neovasc Inc.

Related Categories

Press Releases

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?